CORP-2

COlchicine for Recurrent Pericarditis 2 — multiple recurrences

Patient / Population Intervention / Exposition Comparaison Critère de jugement

In 240 patients with at least two prior recurrences of pericarditis, colchicine for 6 months added to conventional anti-inflammatory therapy reduced further recurrent pericarditis compared with placebo.

240

Schéma

Double-blind, placebo-controlled RCT

Critère

Recurrent pericarditis (intention-to-treat)

Pertinence

Résultat21.6 % vs 42.5 % (RR 0.49; 95 % CI 0.24–0.65; p=0.0009; NNT 5). No serious adverse events.

Imazio M, Belli R, Brucato A, et al. Lancet. 2014;383(9936):2232-2237. 10.1016/S0140-6736(13)62709-9

Discussion et critique

Four northern-Italian hospitals and a predominantly idiopathic case mix, with open follow-up beyond six months limiting inference about optimal duration. It closed the last gap in the colchicine story and extends the drug to every colchicine-naïve relapse, however many have gone before.